Abbott Labs (ABT) Pipeline Makes Headlines but 2 Products Are Churning Out Record Results - Cowen
Tweet Send to a Friend
Cowen analyst Joshua Jennings reiterated an Outperform rating and $140.00 price target on Abbott Labs (NYSE: ABT) ahead of clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
